Zobrazeno 1 - 10
of 163
pro vyhledávání: '"2-HG"'
Autor:
William J. Yin
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
A significant proportion of lower-grade glioma as well as many other types of human cancers are associated with neomorphic mutations in IDH1/2 genes (mIDH1/2). These mutations lead to an aberrant accumulation of 2-hydroxyglutarate (2-HG). Interesting
Externí odkaz:
https://doaj.org/article/1872dcbb6c844c7e941139e594b5afd4
Autor:
Wangqi Tian, Weitong Zhang, Yifan Wang, Ruyi Jin, Yuwei Wang, Hui Guo, Yuping Tang, Xiaojun Yao
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Isocitrate dehydrogenase (IDH) is the key metabolic enzyme that catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG). Two main types of IDH1 and IDH2 are present in humans. In recent years, mutations in IDH have been observed in several
Externí odkaz:
https://doaj.org/article/a8924e3207884932bca40f13c9714948
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The inhibition of alpha-ketoglutarate (α-KG)-dependent dioxygenases is thought to contribute to isocitrate dehydrogenase (IDH) mutation-derived malignancy. Herein, we aim to thoroughly investigate the expression pattern and prognostic significance o
Externí odkaz:
https://doaj.org/article/0dcffdcdcdab4b13a2325014862a8da5
Autor:
Makoto Nakagawa, Masayuki Yamaguchi, Makoto Endo, Yukino Machida, Ayuna Hattori, Fumie Tanzawa, Shinji Tsutsumi, Issay Kitabayashi, Akira Kawai, Fumihiko Nakatani
Publikováno v:
Journal of Bone Oncology, Vol 34, Iss , Pp 100430- (2022)
Background: Chondrosarcoma is a common form of malignant bone tumor with limited treatment options. Approximately half of chondrosarcomas harbor gain-of-function mutations in isocitrate dehydrogenase (IDH), and mutant IDH produces 2-hydroxyglutarate
Externí odkaz:
https://doaj.org/article/2608c96933974fcbb235adc9d90b84cb
Autor:
Mengli Zhang, Huaichao Zhang, Minjie Fu, Jingwen Zhang, Cheng Zhang, Yingying Lv, Fengfeng Fan, Jinsen Zhang, Hao Xu, Dan Ye, Hui Yang, Wei Hua, Ying Mao
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
B7H3 (also known as CD276) is a co-stimulator checkpoint protein of the cell surface B7 superfamily. Recently, the function beyond immune regulation of B7H3 has been widely studied. However, the expression preference and the regulation mechanism unde
Externí odkaz:
https://doaj.org/article/e15e543b1e944b46a3a3dc27fe4dbba6
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Isocitrate dehydrogenase (IDH) is a key metabolic enzyme catalyzing the interconversion of isocitrate to α-ketoglutarate (α-KG). Mutations in IDH lead to loss of normal enzymatic activity and gain of neomorphic activity that irreversibly converts
Externí odkaz:
https://doaj.org/article/8dcefe4504b74aefa1c86c70c05838a3
Publikováno v:
Biomedicines, Vol 10, Iss 6, p 1359 (2022)
The oncometabolite 2-hydroxyglutarate (2-HG) plays a key role in differentiation blockade and metabolic reprogramming of cancer cells. Approximatively 20–30% of acute myeloid leukemia (AML) cases carry mutations in the isocitrate dehydrogenase (IDH
Externí odkaz:
https://doaj.org/article/fe55ae39d16d4d60bf4c6e011462c883
Publikováno v:
Metabolites, Vol 11, Iss 8, p 480 (2021)
The biguanide drug metformin has been widely used for the treatment of type 2 diabetes, and there is evidence supporting the anticancer effect of metformin despite some controversy. Here, we report the growth inhibitory activity of metformin in the b
Externí odkaz:
https://doaj.org/article/adf5ea9dd3e6409c90d59e0efb32945c
Autor:
Zhentao Yang, Bin Jiang, Yan Wang, Hengxiao Ni, Jia Zhang, Jinmei Xia, Minggang Shi, Li-Man Hung, Jingsong Ruan, Tak Wah Mak, Qinxi Li, Jiahuai Han
Publikováno v:
Cell Reports, Vol 19, Iss 9, Pp 1846-1857 (2017)
2-hydroxyglutarate-(2-HG)-mediated inhibition of TET2 activity influences DNA hypermethylation in cells harboring mutations of isocitrate dehydrogenases 1 and 2 (IDH1/2). Here, we show that 2-HG also regulates DNA methylation mediated by DNA methyltr
Externí odkaz:
https://doaj.org/article/5561e3556d15484aaec36954de27a045
Publikováno v:
Journal of Blood Medicine, Vol Volume 7, Pp 171-180 (2016)
Johanna Mondesir1,2 Christophe Willekens3–5 Mehdi Touat6,7 Stéphane de Botton3–5 1Service d’Immunopathologie Clinique, Hôpital Saint Louis, 2CNRS UMR8104, INSERM U1016, Institut Cochin, Université Paris Descartes, Paris, 3Gustave Roussy, Uni
Externí odkaz:
https://doaj.org/article/89d7d87d9bf64724bb600197cf26475c